| A3 Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes. | |
| | |
MedLine Citation:
|
PMID: 22300387 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Diabetes mellitus categorized as type I and II, is a disease of pancreatic insulin, affecting blood glucose level in the body. Recent evidence suggests that cardiac diseases such as hypertension, coronary artery disease, congestive heart failure, and diabetic cardiomyopathy are associated with diabetes and hyperglycemia. The adenosine receptors (AR) have been reported to play an important role in the regulation of these diseases. Four adenosine receptors have been cloned and characterized from several different mammalian species. The receptors are named adenosine A1, A2A, A2B, and A3. The A2A and A2B receptors preferably interact with members of the Gs family of G proteins and the A1 and A3 receptors with Gi/o proteins. The ubiquitous levels of adenosine are found in each cell in normal conditions but in disease conditions its level has been shown to increase and activate G-protein mediated signaling pathway leading to artery constriction in cardiovascular diseases and diabetes. Various studies have demonstrated that A3AR is a potent cardioprotectant during myocardial ischemeia/ischemic reperfusion. Role of A3AR receptor as a possible cardioprotectant in diabetes is under investigation and studies have verified the involvement of cyclooxygenases (COXs) and NADPH oxidase pathways. This review summarizes the possible role of A3AR in cardiovascular disease and discusses advancement in the development of therapeutic agents targeting cardioprotection with discussion on recent patents on A3 agonists that are being utilized in the clinical setting. We anticipate that detailed pharmacological studies of adenosine A3 receptors could help in understanding the link between cardiovascular disease and diabetes and this can be utilized to develop newer therapies that selectively target A3 receptor to overcome cardiac challenges. |
| | |
Authors:
|
Shamama Nishat; Hiba Shabir; Asfar S Azmi; Habib R Ansari |
Related Documents
:
|
19526397 - Serum levels of matrix metalloproteinases mmp-2 and mmp-9 and their inhibitors in women... 9128807 - Cardiac and extracardiac complications in infants of diabetic mothers and their relatio... 19546757 - Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy. 15223227 - In an aboriginal birth cohort, only child size and not birth size, predicts insulin and... 21810597 - Increased vldl-triglyceride secretion precedes impaired control of endogenous glucose p... 6751597 - Serum calcium fractions in diabetes mellitus. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-2-2 |
Journal Detail:
|
Title: Recent patents on cardiovascular drug discovery Volume: - ISSN: 2212-3962 ISO Abbreviation: Recent Pat Cardiovasc Drug Discov Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-2-3 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101263805 Medline TA: Recent Pat Cardiovasc Drug Discov Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Karmanos Cancer Institute, Wayne State University, Detroit MI, 48201, USA; Tel: +1 313 576 8328; Fax: +1 313 576 8389; azmia@karmanos.org. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Whole genome microarray of the major pelvic ganglion after cavernous nerve injury: new insights into...
Next Document: Lens thickness and associated factors.